
News|Articles|October 12, 2012
Intranasal fentanyl spray benefits compared with oral agents for breakthrough cancer pain
Patients with breakthrough cancer pain (BTCP) may want to consider intranasal fentanyl spray over oral agents to treat their breakthrough pain because of improved onset of analgesia and avoidance of nausea and vomiting, according to a report published online for The Annals of Pharmacotherapy.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Optimal Physical Activity for Preventing Digestive System Cancers
2
Tubeless AID Systems Boost HRQoL in Type 1 Diabetes
3
Navigating Female Sexuality in Midlife Requires Provider Nuance and Patient Advocacy
4
Modeling Finds the Timing of Modafinil to Treat Narcolepsy Matters for Efficacy
5

















































